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Abstract
The therapeutic efficacy of systemic drug delivery vehicles depends on their ability to evade the
immune system, cross the biological barriers of the body and localize at target tissues. Leukocytes
possess all of these functions and exert their targeting ability through cellular membrane
interactions. Here we show that NanoPorous Silicon particles (NPS) can successfully perform all
these actions when coated with cellular membranes purified from white blood cells. These hybrid
particles called LeukoLike Vectors (LLV) were able to: prevent rapid clearance of phagocytic
cells of the immune system; communicate with endothelial cells through receptor-ligand
interaction; transport and release a payload across an inflamed reconstructed endothelium.
Furthermore, LLV retained their functions when injected in vivo, showing enhanced circulation
time and improved accumulation in the tumour.
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Supplementary information accompanies this paper at www.nature.com/naturenanotechnology.
Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/.
The authors declare competing financial interests.
Authors’ Contribution Statement.
A. P. supervised all cellular experiments, interpreted the data and wrote the manuscript; N. Q. developed and optimized protocols
Leukolike Vector assembly; A.V. designed and performed all intravital microscopy experiments and analysis and wrote the paper; C.
C. manufactured the NPS; M.E. optimized the development of the system; J.O.M. carried out and analysed time-lapse microscopy
experiments; B.B. performed confocal microscopy and flow cytometry; S. K. performed the physical and chemical characterization; I.
K. Y. performed SEM and assisted with analysis; M.V.E. performed the transwell assays; L.I. optimized in vitro flow systems; M. F.
performed the final edits of the manuscript and mentored the authors during the development of the project; E. T. conceived the LLV
concept, wrote the paper and was the PI of the major supporting grants.
NIH Public Access
Author Manuscript
Nat Nanotechnol. Author manuscript; available in PMC 2013 August 23.
Published in final edited form as:
Nat Nanotechnol. 2013 January ; 8(1): 61–68. doi:10.1038/nnano.2012.212.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Biophysical barriers protect the body by regulating the trafficking, exchange, and clearance
of foreign materials 1. For example, endothelial cells of blood vessels are responsible for
identifying and capturing potential hazards 2. Upon entering the blood, systemically injected
drugs and particles are tagged with proteins (a process called opsonisation3) for subsequent
removal by the body’s immune system known as the mononuclear phagocyte system 4.
Therefore, to function properly, systemic agents must avoid clearance by the immune
system, negotiate past the vascular barrier, and localize at the target tissue in sufficient
quantities 5.
Encapsulating free drugs in nanoparticles is advantageous because it prolongs the drug half-
life, improves its site-specific targeting, reduces side-effects and enhances therapeutic
efficacy without requiring alterations to the chemistry of the drug 6–8. Moreover, the
physical and chemical properties of the nanoparticles themselves confer new capabilities in
vivo 9, 10. For example, optimization of particles’ size 11, 12, shape 13, and surface charge 14,
enhance passive tumour targeting via a mechanism known as enhanced permeation and
retention 15. Furthermore, modification of the surfaces of particles with polyethylene glycol
(PEG) improves biodistribution of chemotherapeutics 16, while bioconjugation of active
targeting molecules enhances delivery to specific cells 17, 18. More recently, efforts have
focused on the development of multistage vectors that decouple each of these functions in
vivo 19. Based around a NanoPorous Silicon (NPS) platform 18, 20, these particles can carry
a variety of cargoes20–22, navigate through blood flow 21, 23, recognize and bind specific
endothelial targets23, 24, and protect therapeutic cargo for enhanced efficacy22, 25.
Yet, particle-based drug delivery has not reached its full therapeutic potential 21, 26.
Avoiding opsonization and non-specific clearance remains a challenge 27 and the use of
PEG can not completely prevent clearance 28 and eventually activate the human complement
system 29. Particles with longer circulation times have shown increase probability of
tumoritropic accumulation in tumours with fenestrated endothelia 30, 31. Regrettably, not all
tumors are characterized by increased vessel permeability. Under these circumstances, the
use of current delivery systems is highly ineffective and the negotiation of the vascular
barriers is a mandatory step to attain the desired drug biodistribution and acceptable
therapeutic indices.
Given the complexity of mass transport in vascular compartment, it is not surprising that
“biomimetic camouflage” strategies are gaining popularity 32, 33. Virus-based carriers 34,
targeted protocells 35, and bio-nano hybrid systems36, 37 have been proposed as potential
strategies for overcoming vascular barriers to drug delivery. Here we describe an approach
to transfer bioactive cellular components to the surface of synthetic particles in order to
confer unique functions not otherwise attainable through current bioconjugation techniques.
This new generation of injectable carriers, named LeukoLike Vectors (LLV), are produced
by camouflaging NPS particles with cellular membranes isolated from freshly harvested
leukocytes. Using a combination of in vitro and in vivo experiments, we show that LLV are
able to avoid opsonisation, delay uptake by the mononuclear phagocyte system,
preferentially bind inflamed endothelium, and facilitate chemotherapeutics transport across
the endothelium while eluding the lysosomal pathway.
Assembly and characterization
LLV were produced by cloaking NPS with cellular membranes isolated from freshly
harvested leukocytes (Figure 1A). The membranes were purified by ultracentrifugation
through a discontinuous sucrose density gradient (Supplementary figure S2), and
reconstituted as proteo-lipid patches. Self-assembly of the LLV was driven by electrostatic
and hydrophobic interactions between the negatively charged proteo-lipid patches and the
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positively charged NPS surface (Figure 1B). As a result, the zeta potential of the (3-
aminopropyl)triethoxysilane (APTES) modified NPS surface switched from +7.41 mV to a
negative value similar to that of leukocytes (LLV: −26 mV, Leukocytes: −31.16 mV)
(Supplementary table 1). Fourier transform infrared spectroscopy (Supplementary figure S3)
suggested that the system was at least partially stabilized by amide bonds between the
carboxylic groups of the proteo-lipids and amine groups on the NPS surface (Figure 1C).
The lipid: particle ratio and vesicle lamellarity was varied to modulate the uniformity,
thickness, and surface stability of the coating (Figure 1D–F). Fusion between adjacent
proteo-lipid patches and lipid vesicles resulted in complete coverage of the particle surface
(Figure 1G–I). The resulting LLV appeared to retain critical leukocyte transmembrane
proteins in the same orientation as their donor cells. Both CD45 and CD3z, two biomarkers
expressed on the membrane of leukocytes 38, and Lymphocyte Function-associated Antigen
1 (LFA-1 or CD11a), an adhesion molecule utilized by leukocytes for vascular
extravasation 39–41, were confirmed to be exposed on the LLV surface using
immunoblotting and flow cytometry (Supplementary figure S2, S4). LLV composition and
stability were evaluated over time through thermogravimetric analysis and scanning electron
microscopy (SEM) (Supplementary figure S5–6). After 24 hours, more than half of the
membrane coating remained associated with the particles, resulting in delayed particle
degradation and cargo release kinetics (Supplementary figure S7).
Inhibition of particle opsonization and reduced phagocytosis
The LLV surface was stained for sialic acid and N-acetylglucosamine glycans, two typical
post-transcriptional modifications of transmembrane proteins that play a key role in the
cellular self-recognition mechanisms42. Their presence was quantified by
spectrofluorimetric quantification of wheat germ agglutinin absorption on the NPS and LLV
surface (Figure 2A). The LLV coating was found to also protect the particle surface from
opsonization by highly abundant serum proteins. LLV incubated with fluorescent IgG and
bovine serum albumin demonstrated significantly less (~10-fold decrease) protein
absorption than NPS (Figure 2B–C).
The ability of the LLV coating to inhibit particle internalization was studied using murine
J774 macrophages and human THP-1 phagocytic cells. Both cell lines were individually
incubated with equivalent numbers of fluorescently labelled NPS and LLV particles coated
with the membranes of each cell type. Particle internalization was quantified using flow
cytometry three hours after treatment (Figure 2D–E). The LLV coating was found to
significantly decrease particle uptake, particularly when the donor membrane matched that
of the host phagocytic cell. Particles coated with J774 membranes showed a ~75% decrease
in uptake by J774 cells whereas particles coated with THP-1 membranes showed a ~50%
decrease in uptake by THP-1 cells. Mismatch between the donor and host cells instead led to
a limited decrease in uptake (~50% for THP-1 LLV and ~10% for J774 LLV). These trends
were also observed using Time Lapse Microscopy (TLM) (Supplementary figure S8,
Supplementary movies 1–6,). No significant impact on cell viability or particle toxicity was
observed following LLV treatment (Supplementary figure S9). This evidence suggests that
the particle opsonization and the consequent specific clearance are inhibited by the
membrane coating and that the source of the cellular membrane can affect the rate of
internalization, depending on the experimental model used.
Vascular intra and intercellular trafficking of LLV
The interaction of LLV with a confluent monolayer of human umbilical vein endothelial
cells (HUVEC) was studied using NPS particles coated with Jurkat cell membranes,
henceforth simply referred to as LLV. As previously reported 43, early NPS internalization
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(~15 min) was characterized by the formation of filopodia “cages” that surrounded and
locked particles against the cell surface. While untreated endothelium appeared smooth and
regular under SEM (Supplementary figure S10), NPS-treated endothelium showed several
irregularities, including the formation of membrane protrusions and abundant outward
vesicle budding (Figure 3A). In contrast, LLV treatment did not induce any notable change
in the cell membranes and LLV internalization involved neither filopodia nor vesicle
formation (Figure 3A). Differences remained after complete particle uptake (~60 min), with
NPS particles still recognizable immediately below the cell surface while the cells displayed
several ring-like structures in association with LLV internalization events (Figure 3A).
Immunostaining of LLV surface revealed a punctate and regularly spaced distribution of
LFA-1 across the particle (Supplementary Figure 11). We postulated that LFA-1 would play
an important role in LLV recognition of and binding to inflamed endothelium. The ability of
LLV to recruit LFA-1 receptor ICAM-1, a cell adhesion molecule over-expressed following
TNF-α stimulation44, was studied under physiological flow using an inflamed endothelium
model (Figure 3B). LLV adhering to the endothelial surface were able to locally induce
clustering of ICAM-1. In contrast, ICAM-1 was homogenously distributed before LLV
administration or following NPS administration. ICAM-1 clustering was inhibited by pre-
treating LLV with an antibody against the active site of LFA-1. Typical clustering events
between ICAM-1 and LLV are shown in the rainbow colour insets (Figure 3B). LLV and
NPS also displayed markedly different adhesion to healthy and inflamed endothelial cell
monolayers under flow (Figure 3C). Under both normal and inflamed conditions, NPS
showed a high quantity of binding to endothelium whereas LLV doubled their binding upon
HUVEC pre-treatment with TNF-α. The increase in LLV binding appeared to be mediated
by LFA-1, since its blockage by an antibody reduced LLV binding to the endothelium.
Confocal microscopy studies performed during LLV and NPS internalization revealed local
rearrangements of the cytoskeleton around LLV, whereas NPS failed to alter the architecture
and distribution of actin filaments (Figure 3D–E). Interestingly, actin filaments surrounding
LLV appeared to be organized in a channel-like formation. Three-dimensional confocal z-
stacks demonstrated “basket-like structures” protruding from the basal side of the cell and
associated with the LLV (Supplementary movies S7–8). The subcellular localization of LLV
and NPS was analysed by TEM for up to 24 hours, demonstrating that internalized LLV
were able to avoid lysosomal sequestration (Figure 3F and Supplementary figure S12–13).
LLV appeared to retain their leukocyte coating (see black arrow in the right inset) and were
in direct contact with the cell cytoplasm, whereas NPS remained trapped inside the
endolysosomal compartment (see black arrow in the left inset) and were trafficked toward
the perinuclear region as previously described45.
The ability of LLV to cross a reconstructed endothelial monolayer was studied in vitro using
a transwell system (Figure 4A) under physiologic and inflammatory conditions. LLV and
NPS were added to a confluent HUVEC monolayer for 3 hours, in the presence and absence
of TNF-α. Particle distribution was evaluated in the three compartments that characterize a
transwell system: free particles in upper chamber, entrapped particles in the endothelial
monolayer and particles transported through the monolayer and recovered in the lower
chamber (Figure 4B, Supplementary figure S14). Under normal conditions (no TNF-α), the
quantity of LLV recovered from the upper chamber was significantly higher than the
quantity of NPS recovered (~25% vs. ~5% respectively). Only a small percentage of both
particle types migrated to the other side of the filter; instead ~75% of LLV and ~90% of
NPS were found inside endothelial cells. In the presence of TNF-α, the quantity of LLV
recovered from the bottom chamber increased significantly from ~2% to ~70%. A relative
decrease in the number of particles found in the supernatant and intracellular compartments
accompanied this change. NPS transport increased to a lesser degree, from ~2% to ~30%,
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with >50% of NPS remaining in the intracellular compartment. This data showed that in the
presence of inflamed conditions, the membrane coating increases particle transportation
through an endothelium monolayer, thereby increasing the permeability of this biological
barrier.
The ability of LLV to increase the permeability of inflamed HUVEC monolayers was
measured assessing the transendothelial electrical resistance (TEER). Compared to NPS, the
treatment of the endothelial monolayers with LLV resulted in a transient drop in resistance.
The maximal drop occurred after 20 minutes of incubation, yielding a ~35% drop in TEER
(Figure 4C). No significant change in TEER was observed with NPS addition, suggesting
that the ~4-fold relative difference between LLV and NPS transport is mediated by the
biomimetic coating.
The therapeutic potential of LLV was assessed using a similar transwell model comprised of
a confluent HUVEC monolayer in the upper chamber and a confluent MDA-MB-231 breast
cancer cell monolayer in the bottom chamber. Particles were loaded with Doxorubicin
(DOX), and the cytotoxic activity of DOX-loaded particles was compared to that of free
DOX 48 hours after treatment (Figure 4D). Both free DOX and DOX-NPS had little effect
on tumour cell viability, reducing MDA-MB-231 viability by ~20% and ~10% respectively.
Most of the DOX-induced cytotoxic effect was observed in the endothelial cell layer, whose
viability was reduced by ~73% and ~71% respectively. In contrast, LLV reduced cancer cell
viability by ~57% while maintaining more than ~80% of the endothelial layer’s viability.
Taken together, this data suggest that LLV can successfully transport the DOX payload
through the endothelium and effectively release it in the lower chamber.
Delayed liver clearance and tumour accumulation in mice
The ability of LLV to evade the mononuclear phagocyte system and accumulate within
tumours in vivo was quantified by tracking individual particles using intravital microscopy.
Systemically administered murine-derived J774 LLV showed delayed accumulation in the
liver, indicating that the integrity of the biomimetic camouflage is retained for up to 40
minutes in vivo (Figure 5A). This time-dependent accumulation was largely mediated by
phagocytic Kupffer cells; however, we observed a statistically significant subset of adherent
LLV (p<0.05) which was not internalized by Kupffer cells (Figure 5B). These non-
phagocytized LLV (~25% of adherent LLV) were generally associated with the liver
endothelium (Figure 5C, arrows) rather than the surface of Kupffer cells. The tumoritropic
accumulation of LLV in mice inoculated with murine B16 melanoma was enhanced
compared to that of NPS (Figure 5D). Particle coating using leukocyte membranes led to a
~2-fold increase in particle density at the tumour across all mice examined. Competition
experiments of differentially labelled particles (Figure 5E, 5F) showed that LLV and NPS
adhered to the tumour endothelium in a time-dependent manner.
Conclusions
The development of efficient systemic drug delivery vehicles requires evasion of the
mononuclear phagocyte system, preferential localization to the target organ, and negotiation
past the endothelial barrier. These properties are crucial for delivering therapeutic quantities
of drug to the tissue of interest 26, 31, 46. In this study, we showed that leukocyte-based
biomimetic camouflage was able to provide a competitive advantage for overcoming
sequential vascular barriers by reducing opsonisation, leveraging self-recognition
mechanisms to delay phagocytic uptake, binding inflamed endothelium, and facilitating
transport across the endothelial layer while eluding the lysosomal pathway. Furthermore,
LLV appeared sufficiently stable in vivo to enhance particle circulation time and improve
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tumoritropic accumulation. Taken together, these results suggest that LLV may be well
suited for chemotherapeutics delivery to cancer.
Unlike conventional nanocarriers, which rely on passive enhanced permeation and retention
effects to accumulate in tumours 31, 47, LLV have the potential to recognize and bind tumour
endothelium in an active, non-destructive manner. It is intriguing to contemplate that future
tumoritropic drug carriers will avoid the need for fenestrated endothelium48 and alleviate
concerns regarding particle-induced injury to endothelial barrier function49. While
additional studies will follow to address LLV stability, immunogenicity, transport, and
pharmacokinetics in vivo, this proof-of-concept study demonstrates that it is possible to
successfully transfer bioactive cellular components to a synthetic system in order to improve
the negotiation of vascular barriers.
Materials and Methods
Cell Culture
Jurkat, THP-1, J774, HUVEC and MDA-MB-231 cell lines were purchased from the
American Type Culture Collection (ATCC; US) and cultured according to the vendor
directions. HUVEC were used within the first 10 passages of culture and stimulated with
TNF-α (10 ng/ml) (e-Bioscience) for 24 hours before co-incubation with particles. In all the
experiments, the particle: cell ratio was 5:1, unless otherwise indicated.
Leukolike Vector Assembly
NPS of 3.2 μm diameter, functionalized with APTES, were incubated with leukocyte
proteo-lipid membranes as described in the Supplementary Information. Chemical and
physical particle analysis and drug loading/release, are described there as well.
Confocal Microscopy
HUVEC were seeded at 75,000 cells/filter on ThinCerts™ inserts (8 μm pore size) coated
with fibronectin and co-incubated with NPS or Jurkat LLV (tagged with PE-Rhod and
DyLight 488 respectively) for 3 hours. After treatment, cells were fixed and stained for actin
using Alexa Fluor 594-phalloidin as described in Serda et al. HUVEC cell monolayers
treated with NPS and Jurkat LLV under flow (see below) were stained for ICAM-1
expression using anti-ICAM-1 (Abcam) followed by IgG-488 (Invitrogen). Images were
acquired using an upright Leica DM6000 or inverted Nikon A1 confocal microscope
equipped with spectral detector and 63x oil-immersion objective. Fluorescence line intensity
profiles and topographic intensity plots of ICAM-1 clustering were analysed using Nikon
Elements v3.2 to distinguish between free, adherent, and internalized particles. Particle
counts were performed manually using high-resolution image mosaics of the entire slide.
Zeta-stacks, collected at 0.7μm intervals, were deconvoluted using AutoQuant Blind
Deconvolution within Nikon Elements. 3D reconstructions and movies were prepared using
the same software.
Endothelial Permeability Assessment
HUVEC were seeded at 80,000 cells/filter on ThinCerts™ inserts coated with fibronectin
(10mg/ml) and co-incubated with NPS or Jurkat LLV at a particle: cell ratio of 2:1 for 3
hours. For each experiment, 6 replicates were performed in addition to 2 controls without
cells. After incubation, the media was collected from each chamber. Lower chambers were
washed with PBS and scraped twice to recover all particles. The filters with adhering cells
were rinsed twice with PBS. Collected particles were centrifuged, resuspended in PBS, and
spotted on 8-chamber slides. The number of particles was estimated by counting 5 randomly
selected fields (20x magnification) under wide-field fluorescence using a Nikon TiE
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inverted microscope. The total number of particles was calculated by multiplying the
number of particles in the observed field by the number of fields within the total area. The
number of filtered LLV was adjusted relative to the cell-free control to correct for particle
entrapment in the filter itself (supplementary figure 14). For the assessment of the payload
transport, transwell chambers were prepared as described above. MDA-MB-231 cells were
cultured at a density of 60% on the lower chamber. Particles were added to the upper
chamber at a particle: cell ratio of 5:1 for 48 hours, after which cell viability was assayed
using an MTT assay as recommended by vendor instructions.
Trans Endothelial Electrical Resistance (TEER) Measurement
The TEER of confluent HUVEC monolayers (seeded as previously described) was measured
at 20-minute intervals before and after particle addition (20 particles/cell) using an EVOM2
voltmeter (World Precision Instruments).
Animal models
Transgenic Tie2-GFP mice (Jackson Labs) and wild-type C57BL/6J mice (Charles River
Laboratories) were utilized for all in vivo studies. Melanoma tumours were generated in the
flank of C57BL/6J mice by a one-time subcutaneous injection of 106 murine B16 cells. The
tumour vasculature was delineated by a one-time injection of 40kDa FITC-dextran tracer
(Invitrogen). Three days prior to imaging, Tie-2 GFP+ mice received a one-time injection of
DiD-labeled autologous red blood cells23 to label Kupffer cells. All animal protocols were
reviewed and approved by the IACUC at The Methodist Hospital Research Institute.
Intravital Microscopy (IVM)
In vivo particle dynamics were imaged in real-time as described in50 using a Nikon A1R
laser scanning confocal microscope adapted for IVM50. Isoflurane anesthetized mice were
surgically prepared as in50, intravenously treated one or two doses of 0.5 × 107 particles in
50 μl PBS, and monitored for up to 3 hours. Particle accumulation and phagocytosis was
quantified using Image J v1.45 (NIH) and NIS Elements v4.1 as in50.
Statistical Analysis
All the data are the result of a minimum of three independent experiments. Statistics were
calculated with Prism GraphPad software (LaJOlla, California, USA). The significance was
calculated through OneWay Anova method, followed by Dunnett’s test or with independent
Student’s T-Test.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
The authors acknowledge the Alliance for NanoHealth Department of Defence Telemedicine & Advanced
Technology Research Center 09 - W81XWH-10-2-0125; Defense Advanced Research Projects Agency -
W911NF-11-1-0266; National Institute of Health U54CA143837 and U54CA151668, Department of Defense/
Breast Cancer Research Program (W81XWH-09-1-0212); N. Q. was supported from Ministero Istruzione
Universita Ricerca, Italy; A. P. was supported from the Bianca Garavaglia Association, (Busto Arsizio, Varese,
Italy); J.O.M. was supported by the National Institute of Health Center for Clinical and Translational Sciences,
Clinical and Translational Award TL1 RR024147 from the National Center for Research Resources; M. V. E. was
supported by Euroclone S.p.a. The content is solely the responsibility of the authors and does not necessarily
represent the official views of the National Center for Research Resources or the National Institutes of Health.
The authors thank Masserini M. E., Agostini M. Nitti D. and Hussain F. for their mentoring role, Liu X. for the
fabrication of the nanoporous silicon particles, Dunner K. Jr. for the assistance with transmission electron
Parodi et al. Page 7
Nat Nanotechnol. Author manuscript; available in PMC 2013 August 23.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
microscopy, Cui K. and The Methodist Hospital Research Institute Advanced Cellular and Tissue Microscope Core
Facility for time-lapse live cell microscopy, Haviland D. and The Methodist Hospital Research Institute Flow
Cytometry Core Facility and De Rosa E. for data analysis, Warier N., Scaria S., Adriani G., Decuzzi P., Zabre E. V.
and Grattoni A. for technical support and Landry M. G. for graphical assistance.
References
1. Bauer HC, et al. New aspects of the molecular constituents of tissue barriers. J Neural Transm.
2011; 118:7–21. [PubMed: 20865434]
2. Rabanel JM, Aoun V, Elkin I, Mokhtar M, Hildgen P. Drug-loaded nanocarriers: Passive targeting
and crossing of biological barriers. Curr Med Chem. 2012; 19:3070–3102. [PubMed: 22612696]
3. Owens DE 3rd, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric
nanoparticles. Int J Pharm. 2006; 307:93–102. [PubMed: 16303268]
4. Moghimi SM, Davis SS. Innovations in avoiding particle clearance from blood by kupffer cells:
Cause for reflection. Crit Rev Ther Drug Carrier Syst. 1994; 11:31–59. [PubMed: 7704918]
5. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev. 2001;
46:149–168. [PubMed: 11259838]
6. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug
Discovery. 2005; 4:145–160.
7. Banerjee S, Li Y, Wang Z, Sarkar FH. Multi-targeted therapy of cancer by genistein. Cancer Lett.
2008; 269:226–242. [PubMed: 18492603]
8. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: An emerging treatment modality for
cancer. Nat Rev Drug Discov. 2008; 7:771–782. [PubMed: 18758474]
9. Barreto JA, et al. Nanomaterials: Applications in cancer imaging and therapy. Adv Mater. 2011;
23:H18–40. [PubMed: 21433100]
10. Mitragotri S, Lahann J. Physical approaches to biomaterial design. Nat Mater. 2009; 8:15–23.
[PubMed: 19096389]
11. Yuan F, et al. Microvascular permeability and interstitial penetration of sterically stabilized
(stealth) liposomes in a human tumor xenograft. Cancer Res. 1994; 54:3352–3356. [PubMed:
8012948]
12. Yuan F, et al. Vascular permeability in a human tumor xenograft: Molecular size dependence and
cutoff size. Cancer Res. 1995; 55:3752–3756. [PubMed: 7641188]
13. Champion JA, Katare YK, Mitragotri S. Particle shape: A new design parameter for micro- and
nanoscale drug delivery carriers. J Control Release. 2007; 121:3–9. [PubMed: 17544538]
14. Campbell RB, et al. Cationic charge determines the distribution of liposomes between the vascular
and extravascular compartments of tumors. Cancer Res. 2002; 62:6831–6836. [PubMed:
12460895]
15. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy:
Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res.
1986; 46:6387–6392. [PubMed: 2946403]
16. Cho YI, Park S, Jeong SY, Yoo HS. In vivo and in vitro anti-cancer activity of thermo-sensitive
and photo-crosslinkable doxorubicin hydrogels composed of chitosan–doxorubicin conjugates. Eur
J Pharmaceut Biopharmaceut. 2009; 73:59–65.
17. Albrecht H. Trastuzumab (herceptin(r)): Overcoming resistance in her2-overexpressing breast
cancer models. Immunotherapy. 2010; 2:795–798. [PubMed: 21091112]
18. Chiappini C, et al. Tailored porous silicon microparticles: Fabrication and properties.
Chemphyschem. 2010; 11:1029–1035. [PubMed: 20162656]
19. Godin B, Tasciotti E, Liu X, Serda RE, Ferrari M. Multistage nanovectors: From concept to novel
imaging contrast agents and therapeutics. Acc Chem Res. 2011; 44:979–989. [PubMed: 21902173]
20. Tasciotti E, et al. Mesoporous silicon particles as a multistage delivery system for imaging and
therapeutic applications. Nat Nanotechnol. 2008; 3:151–157. [PubMed: 18654487]
21. Ananta JS, et al. Geometrical confinement of gadolinium-based contrast agents in nanoporous
particles enhances t1 contrast. Nat Nanotechnol. 2010; 5:815–821. [PubMed: 20972435]
Parodi et al. Page 8
Nat Nanotechnol. Author manuscript; available in PMC 2013 August 23.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
22. Tanaka T, et al. Nanotechnology for breast cancer therapy. Biomed Microdevices. 2009; 11:49–63.
[PubMed: 18663578]
23. van de Ven AL, et al. Rapid tumoritropic accumulation of systemically injected plateloid particles
and their biodistribution. J Control Release. 2012; 158:148–155. [PubMed: 22062689]
24. Mann AP, et al. E-selectin-targeted porous silicon particle for nanoparticle delivery to the bone
marrow. Adv Mater. 2011; 23:278–282.
25. Shen H, et al. Cancer therapy: Cooperative, nanoparticle-enabled thermal therapy of breast cancer.
Adv Healthcare Mater. 2012; 1:128–128.
26. Michor F, Liphardt J, Ferrari M, Widom J. What does physics have to do with cancer? Nat Rev
Cancer. 2011; 11:657–670. [PubMed: 21850037]
27. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: Critical issues in
pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res. 2003; 42:463–
478. [PubMed: 14559067]
28. Immordino ML, Dosio F, Cattel L. Stealth liposomes: Review of the basic science, rationale, and
clinical applications, existing and potential. Int J Nanomed. 2006; 1:297–315.
29. Gabizon, AA.; FMM. Long circulating liposomes: Old drugs, new therapeutics. Springer-Verlag
and Landes Bioscience; 1998.
30. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the epr effect in
macromolecular therapeutics: A review. J Control Release. 2000; 65:271–284. [PubMed:
10699287]
31. Torchilin V. Tumor delivery of macromolecular drugs based on the epr effect. Adv Drug Deliv
Rev. 2011; 63:131–135. [PubMed: 20304019]
32. Yoo JW, Irvine DJ, Discher DE, Mitragotri S. Bio-inspired, bioengineered and biomimetic drug
delivery carriers. Nat Rev Drug Discov. 2011; 10:521–535. [PubMed: 21720407]
33. Barenholz Y. Sphingomyelin and cholesterol: From membrane biophysics and rafts to potential
medical applications. Subcell Biochem. 2004; 37:167–215. [PubMed: 15376621]
34. Manchester M, Singh P. Virus-based nanoparticles (vnps): Platform technologies for diagnostic
imaging. Adv Drug Deliv Rev. 2006; 58:1505–1522. [PubMed: 17118484]
35. Ashley CE, et al. The targeted delivery of multicomponent cargos to cancer cells by nanoporous
particle-supported lipid bilayers. Nat Mater. 2011; 10:389–397. [PubMed: 21499315]
36. Merkel TJ, et al. Using mechanobiological mimicry of red blood cells to extend circulation times
of hydrogel microparticles. Proc Natl Acad Sci. 2011; 108:586–591. [PubMed: 21220299]
37. von Maltzahn G, et al. Nanoparticles that communicate in vivo to amplify tumour targeting. Nat
Mater. 2011; 10:545–552. [PubMed: 21685903]
38. van Vliet SJ, Gringhuis SI, Geijtenbeek TB, van Kooyk Y. Regulation of effector t cells by
antigen-presenting cells via interaction of the c-type lectin mgl with cd45. Nat Immunol. 2006;
7:1200–1208. [PubMed: 16998493]
39. Carman CV. Mechanisms for transcellular diapedesis: Probing and pathfinding by ‘invadosome-
like protrusions’. J Cell Sci. 2009; 122:3025–3035. [PubMed: 19692589]
40. Millan J, et al. Lymphocyte transcellular migration occurs through recruitment of endothelial
icam-1 to caveola- and f-actin-rich domains. Nat Cell Biol. 2006; 8:113–123. [PubMed:
16429128]
41. Yang L. Icam-1 regulates neutrophil adhesion and transcellular migration of tnf-a-activated
vascular endothelium under flow. Blood. 2005; 106:584–592. [PubMed: 15811956]
42. Rebman B. Tumor immunology. ACP Medicine. 2011; 206:137–151.
43. Serda RE, et al. Mitotic trafficking of silicon microparticles. Nanoscale. 2009; 1:250–259.
[PubMed: 20644846]
44. Barreiro O, et al. Dynamic interaction of vcam-1 and icam-1 with moesin and ezrin in a novel
endothelial docking structure for adherent leukocytes. J Cell Biol. 2002; 157:1233–1245.
[PubMed: 12082081]
45. Ferrati S, et al. Intracellular trafficking of silicon particles and logic-embedded vectors. Nanoscale.
2010; 2:1512–1520. [PubMed: 20820744]
Parodi et al. Page 9
Nat Nanotechnol. Author manuscript; available in PMC 2013 August 23.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
46. Ferrari M. Frontiers in cancer nanomedicine: Directing mass transport through biological barriers.
Trends Biotechnol. 2010; 28:181–188. [PubMed: 20079548]
47. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications.
Nat Rev Drug Discov. 2010; 9:615–627. [PubMed: 20616808]
48. Taurin S, Nehoff H, Greish K. Anticancer nanomedicine and tumor vascular permeability; where is
the missing link? J Control Release. 2012
49. Trickler WJ, et al. Silver nanoparticle induced blood-brain barrier inflammation and increased
permeability in primary rat brain microvessel endothelial cells. Toxicol Sci. 2010; 118:160–170.
[PubMed: 20713472]
50. van de Ven AL, et al. Integrated intravital microscopy and mathematical modeling to optimize
nanotherapeutics delivery to tumors. AIP Adv. 2012; 2:11208. [PubMed: 22489278]
Parodi et al. Page 10
Nat Nanotechnol. Author manuscript; available in PMC 2013 August 23.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1. The LeukoLike Vector
a, A cartoon of LLV: the leukocyte-derived cell membranes fully cover the NPS and seal off
its pores. b, Zoom-in of red box in a. Schematic showing relevant proteins (LFA-1, CD3z,
CD45, Lck) in the membrane are interspersed in the porous structure of the NPS. c,
Schematic showing the interactions between the APTES group on the NPS surface and a
membrane phospholipid (left) and protein (right). Phosphate groups on the phospholipid
form electrostatic/hydrophilic interactions, whereas carboxylic groups of proteins can form
amide bonds. d, Transmission electron micrograph (TEM) of bare NPS reveal the open
pores. e, In the presence of unilamellar vesicles, LLV coating thickness is similar to that of
normal lipid bilayers. f, The coating can reach thicknesses up to 500 nm depending on the
number of membrane layers and the extent of their fusion to the NPS. g–i, Scanning electron
micrograph (SEM) of a bare NPS surface (g), a leukocyte used as a membrane donor (h),
and an NPS camouflaged with leukocyte-derived membranes (i), which appears similar to h.
Scale bars = 100 nm (TEM), 1 μm (SEM).
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Figure 2. Inhibition of particle opsonization and phagocytosis
a, Staining of the LLV (green box) and NPS (red box) particles using wheat germ agglutinin
(particles on right of each box, red) to reveal N-acetylglucosamine and sialic acid groups on
the surface of the NPS and LLV (particles on left of each box, green). Scale bars = 1μm.
Fluorometric quantification demonstrates enhanced LLV staining in the graph below. b,
Differential opsonization by passive absorption of IgG (green, both boxes) to the surface of
NPS (left, red box) and LLV (right, green box). Scale bars = 1 μm. Quantification displayed
in the graph below. c, Albumin (green) absorbs passively to the surface of NPS (left, red
box) and LLV (right, green box). Scale bars = 2μm. Fluorometric analysis reveals the slope
of fluorescence vs particle concentration in the graph below d–e, Internalization of particles
by J774 (d) and THP-1 (e) with coatings derived from either cell line, measured by flow
cytometry following 3hr co-incubation. Values and significance are expressed as relative to
NPS treated cells. ** = p < 0.01, *** = p < 0.001.
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Figure 3. Particle adhesion to healthy and inflamed endothelium
a, SEM micrographs of NPS and LLV uptake by HUVEC cells pre-treated with TNF-α.
Low and high magnifications are shown for each condition (scale bars = 10 and 2 μm
respectively). b, After treatment with NPS, LLV, or LLV pre-incubated with anti-LFA-1
antibody (particles, yellow), ICAM-1 clusters (green, arrows) on particles at the surface of
TNF-α stimulated HUVEC cells. High magnification images and colorimetric analysis of
receptor clustering is shown to the right. Scale bars = 15 and 2 μm. c, Quantification of
particle adhesion to normal (− TNF-α) and inflamed endothelium (+TNF-α) following 30
minutes of flow. ** = p < 0.01, *** = p < 0.001. Black asterisks identify significance
between particle types while orange dots signal differences in TNF-α treated or untreated
groups. d–e, Confocal microscopy of HUVEC treated with NPS (red) or LLV (green) for 3
hours show reorganization of actin filaments (orange). Scale bars = 20 and 10 μm. f, TEM
micrographs of NPS or LLV 6 hours after particle addition show lysosomal sequestration
and cytoplasmic accumulation (respectively) with high magnification images to the right.
Scale bars = 10 μm, 2 μm, and 100 nm.
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Figure 4. LLV effect on endothelial barrier function
a, Schematic of a transwell chamber for assaying transport across a cellular monolayer.
Particles were counted in the upper chamber (1: supernatant), endothelial layer (2:
intracellular), and lower chamber (3: filtered). b, Quantification of particle localization after
3 hours with or without TNF-α demonstrated significantly enhanced transport of LLV
(green dots) compared to NPS (red dots). c, Evaluation of TEER, normalized against
untreated controls. LLV were found to produce a transient decrease in TEER measurements
of confluent inflamed endothelium. d, Studies of HUVEC (endothelial) and MDA-MB-231
(cancer) cell viability in a transwell system. LLV loaded doxorubicin (DOX LLV) showed
enhanced tumour cell killing and decreased endothelial cell death following 48 hr incubation
compared to free doxorubicin (Free DOX) and NPS loaded doxorubicin (DOX-NPS). * = p
< 0.05, ** = p < 0.01, *** = p <0.001, **** = p < 0.0001.
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Figure 5. Enhanced tumoritropic accumulation in mice
a, Time-dependent accumulation of systemically administered J774-derived LLV and NPS
particles in the liver of live mice. b, Time-dependent avoidance of phagocytosis displayed as
the number of particles not associated with liver macrophages (Kupffer cells). c,
Representative images of LLV (red) accumulation and uptake by Kupffer cells (blue) within
the microvasculature (green) of healthy Tie-2 GFP+ mice, as measured by single-particle
intravital microscopy (IVM). Phagocytized LLV are distinguished by a violet appearance in
multicolour overlay images (see insets). Arrows indicate non-phagocytized LLV. Scale =
100μm. d, Time-dependent accumulation of systemically administered LLV and NPS in
murine B16 melanoma tumours, as measured by single-particle IVM. e, Adhesion of
individual LLV (red) and NPS (blue) particles, indicated by arrows, to the tumour
endothelium (green), imaged and quantified 90 minutes after injection. High magnification
images of boxes shown to the right. Scale = 100μm and 5μm. f, Representative images of
circulating and adherent LLV (red, circles) and NPS (blue, squares) in the melanoma
microvasculature (green). Asterisks indicate adherent particles. Scale bars = 100μm. * =
p<0.05, ** = p<0.01, n=4.
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